MedTrace Logo

Reduction of Remifentanil-related Complications

NCT01003028 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-12-01

No results posted yet for this study

Summary

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

Conditions

  • Anesthesia

Interventions

DRUG

Remifentanil (Limited) - Target Controlled Infusion system

Limit max plasma concentration to 9.8 ng/ml

DRUG

Remifentanil (Control) - Target Controlled Infusion system

Use 20 ng/ml as max plasma concentration

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-12-01
Completion
2026-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01003028 on ClinicalTrials.gov